Across TCGA pan-cancer cohorts, HCAR1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HCAR1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HCAR1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated HCAR1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, STAD, and HNSC are the cancer types where HCAR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.323	.026	12	view →
STAD	OS	Median	All	0.256	0.689	.007	12	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HCAR1 tumor-vs-normal RNA expression · all HCAR1 data types